Today: 9 June 2026
Circle stock (CRCL) rises after-hours as stablecoin regulation battle returns to Washington
15 January 2026
1 min read

Circle stock (CRCL) rises after-hours as stablecoin regulation battle returns to Washington

New York, January 14, 2026, 19:18 EST — After-hours

Circle Internet Group, Inc. shares climbed 1.7% in after-hours trading Wednesday, closing at $84.80. During the day, the stock fluctuated between $81.79 and $88.46. Roughly 14.3 million shares traded hands.

The shift comes as investors zero in on Washington’s approach to drafting new regulations for crypto and dollar-backed “stablecoins” — tokens pegged to the U.S. dollar’s value. For Circle, this isn’t just background chatter; it directly affects how USDC is employed in payments, trading, and settlement.

This week, U.S. senators unveiled a draft bill targeting crypto market structure, aiming to clarify when tokens qualify as securities or commodities and expanding the CFTC’s oversight of spot crypto markets. The proposal would prohibit crypto firms from paying interest solely for holding stablecoins, though rewards linked to activities like payments would remain allowed, alongside stricter disclosure rules, according to the draft and industry feedback. “Their demands to eliminate stablecoin rewards are designed to choke off consumer choice,” said Summer Mersinger, CEO of the Blockchain Association. Reuters

Circle unveiled a report Tuesday outlining its vision for an “internet financial system,” centered on its USDC and EURC stablecoins, a tokenized money market fund called USYC, and a forthcoming “Arc” layer-1 blockchain designed to run applications. The company said USDC onchain volume topped $9.6 trillion in Q3 2025, while its Circle Payments Network hit $3.4 billion in annualized transaction volume since launching in May 2025. “The financial system is going online,” CEO Jeremy Allaire declared. Circle

Stablecoin payments are heating up. On Tuesday, Polygon Labs announced plans to acquire crypto payments company Coinme along with infrastructure provider Sequence for over $250 million. The move follows last year’s passage of the GENIUS Act and aims to boost Polygon’s push into stablecoin transactions, Reuters reported. CEO Marc Boiron described payments as “the killer use case” and expressed Polygon’s ambition to become a regulated U.S. payments player. Coinme, whose investors include Circle, was highlighted in the report. Reuters

Crypto markets picked up steam as Bitcoin climbed roughly 1.5%, with ether inching up around 0.5%. Shares of crypto-linked firms like Coinbase and Galaxy Digital also moved higher.

A separate SEC filing revealed that Circle director Bradley Horowitz moved a small pro-rata distribution of shares linked to an Accel fund into a family trust, not through an open-market sale.

Still, the policy angle works both ways. If lawmakers clamp down on rewards or drag their feet on the bill, traders could see it as another blow to the “regulated stablecoin” narrative — and Circle’s stock has proven it can react swiftly when appetite for crypto risk shifts.

Thursday’s Senate Banking Committee debate is now in the spotlight, with potential amendments poised to alter the stablecoin-rewards portion and challenge industry backing. Coinbase CEO Brian Armstrong told Fortune, “We’d rather have no bill than a bad bill.” Meanwhile, Ron Hammond, Wintermute’s policy chief, cautioned, “it’s crypto and there’s always last-second drama.” Fortune

Stock Market Today

  • Broadcom Stock Set for 27% Gain to $500 Amid AI Growth, Despite Recent Selloff
    June 9, 2026, 10:08 AM EDT. Broadcom (NASDAQ:AVGO) shares dropped nearly 14% post-earnings despite 47.87% revenue growth and an eighth straight earnings per share (EPS) beat. The stock trades around $396.60, with a 24/7 Wall St. price target of $503.61, implying a 26.98% upside over 12 months and a buy recommendation at 90% confidence. Broadcom's Q2 revenue hit $22.19 billion with a 143% jump in AI semiconductor sales to $10.8 billion. CEO Hock Tan projects over 200% AI revenue growth in Q3, targeting $16 billion. Bear risks include heavy insider selling and a high 64 forward P/E ratio. Bulls note strong AI demand, with price targets up to $600 billion revenue potential by 2028. The stock remains 14.82% higher year-to-date despite recent volatility.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals
Previous Story

Morgan Stanley stock slips before earnings as Wall Street digests big-bank signals

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown
Next Story

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown

Go toTop